ES2179049T3 - Oxepano-isomeros de rapamicina utiles como agentes inmunosupresores. - Google Patents

Oxepano-isomeros de rapamicina utiles como agentes inmunosupresores.

Info

Publication number: ES2179049T3
Authority: ES; Spain
Prior art keywords: useful; rapamicina; oxepano; isomeros; immunosuppressing agents
Prior art date: 1992-01-16
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.): Expired - Lifetime

Application number

ES93300207T

Other languages

English (en)

Spanish (es)

Inventor

Philip Floyd Hughes

Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)

Wyeth LLC

Original Assignee

Wyeth LLC

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

1992-01-16

Filing date

1993-01-14

Publication date

2003-01-16

Family has litigation

First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=25235357&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=ES2179049(T3) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.

1993-01-14 Application filed by Wyeth LLC filed Critical Wyeth LLC

2003-01-16 Application granted granted Critical

2003-01-16 Publication of ES2179049T3 publication Critical patent/ES2179049T3/es

2013-01-14 Anticipated expiration legal-status Critical

Status Expired - Lifetime legal-status Critical Current

Links

230000001506 immunosuppresive effect Effects 0.000 title abstract 2
201000010099 disease Diseases 0.000 abstract 2
208000037265 diseases, disorders, signs and symptoms Diseases 0.000 abstract 2
208000023275 Autoimmune disease Diseases 0.000 abstract 1
206010061218 Inflammation Diseases 0.000 abstract 1
230000004054 inflammatory process Effects 0.000 abstract 1
QFJCIRLUMZQUOT-HPLJOQBZSA-N sirolimus Chemical class C1C[C@@H](O)[C@H](OC)C[C@@H]1C[C@@H](C)[C@H]1OC(=O)[C@@H]2CCCCN2C(=O)C(=O)[C@](O)(O2)[C@H](C)CC[C@H]2C[C@H](OC)/C(C)=C/C=C/C=C/[C@@H](C)C[C@@H](C)C(=O)[C@H](OC)[C@H](O)/C(C)=C/[C@@H](C)C(=O)C1 QFJCIRLUMZQUOT-HPLJOQBZSA-N 0.000 abstract 1
238000002054 transplantation Methods 0.000 abstract 1

Classifications

- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
- C07D471/12—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains three hetero rings
- C07D471/18—Bridged systems
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/14—Antivirals for RNA viruses
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/06—Immunosuppressants, e.g. drugs for graft rejection

Landscapes

Health & Medical Sciences (AREA)
Chemical & Material Sciences (AREA)
Organic Chemistry (AREA)
Life Sciences & Earth Sciences (AREA)
General Health & Medical Sciences (AREA)
Animal Behavior & Ethology (AREA)
Chemical Kinetics & Catalysis (AREA)
General Chemical & Material Sciences (AREA)
Medicinal Chemistry (AREA)
Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
Veterinary Medicine (AREA)
Pharmacology & Pharmacy (AREA)
Public Health (AREA)
Virology (AREA)
Immunology (AREA)
Oncology (AREA)
Bioinformatics & Cheminformatics (AREA)
Engineering & Computer Science (AREA)
Communicable Diseases (AREA)
Molecular Biology (AREA)
Transplantation (AREA)
Pain & Pain Management (AREA)
Rheumatology (AREA)
Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
Peptides Or Proteins (AREA)
Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

ES93300207T 1992-01-16 1993-01-14 Oxepano-isomeros de rapamicina utiles como agentes inmunosupresores. Expired - Lifetime ES2179049T3 (es)

Applications Claiming Priority (1)

Application Number	Priority Date	Filing Date	Title
US07/822,171 US5221740A (en)	1992-01-16	1992-01-16	Oxepane isomers of rapamycin useful as immunosuppressive agents

Publications (1)

Publication Number	Publication Date
ES2179049T3 true ES2179049T3 (es)	2003-01-16

Family

ID=25235357

Family Applications (1)

Application Number	Title	Priority Date	Filing Date
ES93300207T Expired - Lifetime ES2179049T3 (es)	1992-01-16	1993-01-14	Oxepano-isomeros de rapamicina utiles como agentes inmunosupresores.

Country Status (9)

Country	Link
US (2)	US5221740A (fr)
EP (1)	EP0552031B1 (fr)
JP (3)	JP3108557B2 (fr)
AT (1)	ATE219084T1 (fr)
CA (1)	CA2086643C (fr)
DE (1)	DE69332005T2 (fr)
DK (1)	DK0552031T3 (fr)
ES (1)	ES2179049T3 (fr)
PT (1)	PT552031E (fr)

Families Citing this family (52)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
CH686761A5 (de)	1993-05-27	1996-06-28	Sandoz Ag	Galenische Formulierungen.
CA2434525C (fr)	1994-08-24	2006-01-03	Canon Kabushiki Kaisha	Reservoir d'encre pour imprimante a jet d'encre, support pour ce reservoir, chariot pour ce support et imprimante a jet d'encre
GB9713730D0 (en)	1997-06-30	1997-09-03	Ciba Geigy Ag	Organic compounds
US20070032853A1 (en) *	2002-03-27	2007-02-08	Hossainy Syed F	40-O-(2-hydroxy)ethyl-rapamycin coated stent
US7807211B2 (en)	1999-09-03	2010-10-05	Advanced Cardiovascular Systems, Inc.	Thermal treatment of an implantable medical device
US6790228B2 (en) *	1999-12-23	2004-09-14	Advanced Cardiovascular Systems, Inc.	Coating for implantable devices and a method of forming the same
US6641611B2 (en)	2001-11-26	2003-11-04	Swaminathan Jayaraman	Therapeutic coating for an intravascular implant
US20040137066A1 (en) *	2001-11-26	2004-07-15	Swaminathan Jayaraman	Rationally designed therapeutic intravascular implant coating
US20050118344A1 (en)	2003-12-01	2005-06-02	Pacetti Stephen D.	Temperature controlled crimping
US20110104186A1 (en)	2004-06-24	2011-05-05	Nicholas Valiante	Small molecule immunopotentiators and assays for their detection
EP1804751A2 (fr) *	2004-10-04	2007-07-11	QLT USA, Inc.	Apport oculaire de preparations d'apport polymere
US8313763B2 (en) *	2004-10-04	2012-11-20	Tolmar Therapeutics, Inc.	Sustained delivery formulations of rapamycin compounds
JP2008533007A (ja) *	2005-03-07	2008-08-21	ワイス	４２−ｏ−（２−ヒドロキシ）エチル−ラパマイシンのオキセパン異性体
US20070203171A1 (en) *	2006-02-28	2007-08-30	Zhao Jonathon Z	Combination of rapamycin and its tetrazole isomers and epimers, methods of making and using the same
US20070203168A1 (en) *	2006-02-28	2007-08-30	Zhao Jonathon Z	Isomers of rapamycin and 42-Epi-rapamycin, methods of making and using the same
US7622477B2 (en) *	2006-02-28	2009-11-24	Cordis Corporation	Isomers and 42-epimers of rapamycin alkyl ether analogs, methods of making and using the same
JP4946751B2 (ja)	2006-11-06	2012-06-06	セイコーエプソン株式会社	容器ホルダ、液体消費装置及び液体収容容器
TW201738095A (zh)	2006-11-06	2017-11-01	Seiko Epson Corp	液體收容容器、容器夾持具、及液體消耗裝置
US8414909B2 (en)	2006-11-20	2013-04-09	Lutonix, Inc.	Drug releasing coatings for medical devices
US8998846B2 (en)	2006-11-20	2015-04-07	Lutonix, Inc.	Drug releasing coatings for balloon catheters
US8414525B2 (en)	2006-11-20	2013-04-09	Lutonix, Inc.	Drug releasing coatings for medical devices
US9737640B2 (en)	2006-11-20	2017-08-22	Lutonix, Inc.	Drug releasing coatings for medical devices
US9700704B2 (en)	2006-11-20	2017-07-11	Lutonix, Inc.	Drug releasing coatings for balloon catheters
US8414910B2 (en)	2006-11-20	2013-04-09	Lutonix, Inc.	Drug releasing coatings for medical devices
US8414526B2 (en)	2006-11-20	2013-04-09	Lutonix, Inc.	Medical device rapid drug releasing coatings comprising oils, fatty acids, and/or lipids
US8425459B2 (en)	2006-11-20	2013-04-23	Lutonix, Inc.	Medical device rapid drug releasing coatings comprising a therapeutic agent and a contrast agent
US20080276935A1 (en)	2006-11-20	2008-11-13	Lixiao Wang	Treatment of asthma and chronic obstructive pulmonary disease with anti-proliferate and anti-inflammatory drugs
JP2008305262A (ja) *	2007-06-08	2008-12-18	Konica Minolta Business Technologies Inc	サーバ及びシンクライアント環境でのプリンタ紹介方法
WO2010024898A2 (fr)	2008-08-29	2010-03-04	Lutonix, Inc.	Procédés et appareils pour poser un revêtement sur des cathéters à ballonnet
ES2645692T3 (es)	2008-11-11	2017-12-07	The Board Of Regents,The University Of Texas System	Microcápsulas de rapamicina y su uso para el tratamiento del cáncer
US20170079962A1 (en)	2009-11-11	2017-03-23	Rapamycin Holdings, Llc	Oral Rapamycin Preparation and Use for Stomatitus
US9283211B1 (en)	2009-11-11	2016-03-15	Rapamycin Holdings, Llc	Oral rapamycin preparation and use for stomatitis
EP2563391B1 (fr)	2010-04-27	2020-08-26	Roche Glycart AG	Polythérapie d'un anticorps CD20 afucosylaté avec un inhibiteur mTOR
US9896730B2 (en)	2011-04-25	2018-02-20	OSI Pharmaceuticals, LLC	Use of EMT gene signatures in cancer drug discovery, diagnostics, and treatment
WO2013013708A1 (fr)	2011-07-26	2013-01-31	Fundació Institut D'investigació Biomèdica De Bellvitge	Traitement du rejet aigu dans une transplantation rénale
CN103705925B (zh)	2012-09-29	2018-03-30	段磊	抑制PI3K/AKT/mTOR信号通路的药物组合
US9750728B2 (en)	2012-09-29	2017-09-05	Targeted Therapeutics, Llc	Method and pharmaceutical composition for inhibiting PI3K/AKT/mTOR signaling pathway
EP2906214A1 (fr)	2012-10-12	2015-08-19	The Board of Regents of The University of Texas System	Utilisation d'inhibiteurs mtor pour traiter le déficit cognitif vasculaire
EP2968281B1 (fr)	2013-03-13	2020-08-05	The Board of Regents of The University of Texas System	Inhibiteurs de mtor pour la prévention de la croissance de polypes intestinaux
CN103739616B (zh) *	2013-12-27	2015-12-30	福建省微生物研究所	含噻唑基雷帕霉素类衍生物及其应用
US9700544B2 (en)	2013-12-31	2017-07-11	Neal K Vail	Oral rapamycin nanoparticle preparations
DK3089737T3 (da)	2013-12-31	2021-12-13	Rapamycin Holdings Llc	Orale rapamycin-nanopartikelpræparater og anvendelse.
AU2015237200A1 (en)	2014-03-27	2016-10-06	The Brigham And Women's Hospital, Inc.	Metabolically-activated drug conjugates to overcome resistance in cancer therapy
WO2015187541A1 (fr)	2014-06-02	2015-12-10	Children's Medical Center Corporation	Procédés et compositions pour une immunomodulation
IL303660A (en)	2017-05-02	2023-08-01	Revolution Medicines Inc	Rapamycin analogs as mtor inhibitors
EP3624863B1 (fr)	2017-05-15	2021-04-14	C.R. Bard, Inc.	Dispositif médical à revêtement d'élution de médicament et à couche intermédiaire
MX2020011564A (es)	2018-05-01	2021-01-29	Revolution Medicines Inc	Analogos de rapamicina unidos a c26 como inhibidores de mtor.
HRP20230488T1 (hr)	2018-05-01	2023-08-04	Revolution Medicines, Inc.	C40-, C28- I C-32-VEZANI ANALOZI RAPAMICINA KAO INHIBITORI mTOR
CN113226389B (zh)	2018-11-14	2022-11-08	乐通公司	在经改性设备表面上具有药物洗脱涂层的医疗设备
JP7487228B2 (ja)	2019-04-08	2024-05-20	バード・ペリフェラル・バスキュラー・インコーポレーテッド	改質されたデバイス表面に薬物溶出コーティングを有する医療用デバイス
US20240382628A1 (en)	2021-07-15	2024-11-21	President And Fellows Of Harvard College	Compositions and methods relating to cells with adhered particles
US12539305B2 (en)	2022-05-25	2026-02-03	Revolution Medicines, Inc.	Methods of treating cancer with an mTOR inhibitor

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
ZA737247B (en) *	1972-09-29	1975-04-30	Ayerst Mckenna & Harrison	Rapamycin and process of preparation
US5100899A (en) *	1989-06-06	1992-03-31	Roy Calne	Methods of inhibiting transplant rejection in mammals using rapamycin and derivatives and prodrugs thereof
GB2246350A (en) *	1990-07-23	1992-01-29	Fujisawa Pharmaceutical Co	Tricyclo compounds
US5091389A (en) *	1991-04-23	1992-02-25	Merck & Co., Inc.	Lipophilic macrolide useful as an immunosuppressant

1992
- 1992-01-16 US US07/822,171 patent/US5221740A/en not_active Expired - Lifetime
1993
- 1993-01-04 CA CA002086643A patent/CA2086643C/fr not_active Expired - Fee Related
- 1993-01-14 JP JP05004754A patent/JP3108557B2/ja not_active Expired - Fee Related
- 1993-01-14 AT AT93300207T patent/ATE219084T1/de not_active IP Right Cessation
- 1993-01-14 DK DK93300207T patent/DK0552031T3/da active
- 1993-01-14 PT PT93300207T patent/PT552031E/pt unknown
- 1993-01-14 EP EP93300207A patent/EP0552031B1/fr not_active Revoked
- 1993-01-14 ES ES93300207T patent/ES2179049T3/es not_active Expired - Lifetime
- 1993-01-14 DE DE69332005T patent/DE69332005T2/de not_active Revoked
- 1993-03-18 US US08/032,910 patent/US5344833A/en not_active Expired - Lifetime
2002
- 2002-10-02 JP JP2002290288A patent/JP2003180385A/ja active Pending
2004
- 2004-05-26 JP JP2004156286A patent/JP2004313196A/ja active Pending

Also Published As

Publication number	Publication date
PT552031E (pt)	2002-09-30
JP2004313196A (ja)	2004-11-11
JPH06312990A (ja)	1994-11-08
US5344833A (en)	1994-09-06
CA2086643C (fr)	2002-11-26
DE69332005T2 (de)	2002-11-14
EP0552031A1 (fr)	1993-07-21
EP0552031B1 (fr)	2002-06-12
US5221740A (en)	1993-06-22
CA2086643A1 (fr)	1993-07-17
JP2003180385A (ja)	2003-07-02
JP3108557B2 (ja)	2000-11-13
DK0552031T3 (da)	2002-09-23
DE69332005D1 (de)	2002-07-18
ATE219084T1 (de)	2002-06-15

Publication	Publication Date	Title
ES2179049T3 (es)	2003-01-16	Oxepano-isomeros de rapamicina utiles como agentes inmunosupresores.
ATE163420T1 (de)	1998-03-15	C-22 ringstabilisierte rapamycin derivate
DE69724811D1 (de)	2003-10-16	Pentafluorobenzensulfonamide und analoge
ES2170101T3 (es)	2002-08-01	Compuesto ciclodepsipeptido.
TR199801919T2 (xx)	1999-02-22	Rapamisin t�revlerinin damar hastal�klar� ve yabanc� doku naklinde kullan�m�.
PT920421E (pt)	2003-03-31	Derivados de isoxazolina uteis como agentes antimicrobianos
ES2119912T3 (es)	1998-10-16	Nuevos aminometilenpeptidos como inmunosupresores.
ES2116471T3 (es)	1998-07-16	Arilcarbonil y alcoxicarbonil carbamatos de rapamicina como agentes inmunosupresores y antifungicos.
MX9306271A (es)	1994-04-29	Carbamatos de rapamicina y composicion farmaceutica que los incluye.
DK0651754T3 (da)	1997-10-27	K-252a-derivater
ATE286055T1 (de)	2005-01-15	Kondensierte pyrrolocarbazole
SV1999000102A (es)	2000-07-06	Compuestos heterociclicos como inhibidores de enzimas de rotamasa. ref. pcs 9475 afae/bb.
ATE136900T1 (de)	1996-05-15	Prolinderivat von rapamycin, seine herstellung und verwendung
ES2177583T3 (es)	2002-12-16	Nuevo compuesto tetraciclico.
AR029214A1 (es)	2003-06-18	Compuestos inhibidores de fosfodiesterasa - 4: 8 - arilquinolinas sustituidas, composiciones farmaceuticas, metodo de tratamiento que las utiliza
BR9712081A (pt)	1999-08-24	Novos derivados de pept¡deos tendo res¡duo tiazolil-alanina
ATE172985T1 (de)	1998-11-15	Sulfonamidaminomethylenderivate als immunsuppressiva
FI945164A7 (fi)	1994-11-02	Biologisesti aktiivisesti ureidojohdannaiset, jotka ovat käyttökelpoisia antimetastaattisina aineina
MX9304626A (es)	1994-02-28	Derivados heterociclicos utiles en el tratamiento de enfermedades cardiovasculares.
DE69637641D1 (de)	2008-09-25	Auf rapamycin basierende regulation biologischer vorgänge
ES2062286T3 (es)	1994-12-16	Compuestos arilicos fenilacetonitriloalquilaminoalquil-orto-sustituidos de utilidad como agentes inmunosupresivos.
DE69611148D1 (de)	2001-01-11	Pyrrolo(4,3,2-de)chinolin-Derivat
UA27752C2 (uk)	2000-10-16	Похідні рапаміцину, що мають індукуючу імунодепресію активність, спосіб індукування імунодепресії, фармацевтична композиція
BR0011832A (pt)	2002-03-05	Uso da proteìna uk 114 para a inibição de rejeição de transplantes de órgãos
ECSP972236A (es)	1998-09-22	Derivados de 6,6- heterobiciclicos sustituidos